Question

A 42-year-old woman presents with progressive fatigue, cutaneous petechiae, and epistaxis. A complete blood count shows hemoglobin 7.8 g/dL, white blood cell count 3.4 x 10^9/L, and platelets 28 x 10^9/L. Bone marrow aspiration demonstrates 12% myeloblasts with Auer rods, and cytogenetic analysis reveals t(8;21)(q22;q22.1) resulting in the RUNX1::RUNX1T1 fusion. Under the WHO 2022 and International Consensus Classification (ICC) systems, what is the correct diagnosis?

Neoplasias Mieloides

Question · Medium

Question

A 34-year-old male is admitted with severe epistaxis, gingival hemorrhage, and extensive purpura. Laboratory tests show WBC 2.1 x 10^9/L, hemoglobin 8.0 g/dL, platelets 18 x 10^9/L, prothrombin time (PT) 21 seconds (INR 1.8), fibrinogen 78 mg/dL, and elevated D-dimer (>20 mcg/mL). The peripheral smear reveals promyelocytes packed with prominent Auer rods in bundles (faggot cells). Bone marrow aspirate is pending for PML::RARA cytogenetics. What is the immediate, life-saving management step?

Neoplasias Mieloides

Question · Easy

Question

On day 5 of induction therapy with ATRA and arsenic trioxide (ATO) for newly diagnosed low-risk acute promyelocytic leukemia, a 38-year-old patient develops fever (38.6°C), unexplained dyspnea, a weight gain of 4.5 kg, bilateral pulmonary infiltrates, and a small pleural effusion. The WBC count has risen from 2.5 x 10^9/L to 18.0 x 10^9/L. Blood cultures are drawn. What is the definitive management for this complication?

Neoplasias Mieloides

Question · Medium

Question

A 58-year-old man is evaluated for an asymptomatic IgG kappa serum monoclonal protein of 3.8 g/dL. His serum calcium is 9.2 mg/dL, serum creatinine is 0.9 mg/dL, and hemoglobin is 13.5 g/dL. Whole-body low-dose CT reveals no lytic bone lesions. However, bone marrow core biopsy demonstrates 65% infiltration by clonal plasma cells. According to the International Myeloma Working Group (IMWG) updated diagnostic criteria, what is the correct diagnosis and management?

Neoplasias Linfoides

Question · Easy

Question

A 31-year-old male receiving ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) for advanced Hodgkin lymphoma develops a persistent dry cough, progressive exertional dyspnea, and bibasilar crackles after his fourth cycle. High-resolution chest CT reveals bilateral subpleural reticular opacities and ground-glass changes. Pulmonary function testing demonstrates a 30% reduction in carbon monoxide diffusing capacity (DLCO) from baseline. What is the immediate and definitive management?

Neoplasias Linfoides

Question · Hard

Loading more…